These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23765227)

  • 41. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Becker H; Maharry K; Radmacher MD; Mrózek K; Metzeler KH; Whitman SP; Schwind S; Kohlschmidt J; Wu YZ; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Moore JO; Caligiuri MA; Larson RA; Marcucci G; Bloomfield CD
    Haematologica; 2011 Oct; 96(10):1488-95. PubMed ID: 21659357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
    Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
    Gaidzik VI; Schlenk RF; Moschny S; Becker A; Bullinger L; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Döhner H; Döhner K;
    Blood; 2009 May; 113(19):4505-11. PubMed ID: 19221039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
    Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
    Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
    Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia.
    Larson RA
    Chem Biol Interact; 2010 Mar; 184(1-2):21-5. PubMed ID: 19822134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.
    Fu L; Fu H; Tian L; Xu K; Hu K; Wang J; Wang J; Jing H; Shi J; Ke X
    Oncotarget; 2016 Mar; 7(13):15828-39. PubMed ID: 26910834
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
    Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
    J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.
    Zhu YM; Wang PP; Huang JY; Chen YS; Chen B; Dai YJ; Yan H; Hu Y; Cheng WY; Ma TT; Chen SJ; Shen Y
    J Transl Med; 2017 Aug; 15(1):178. PubMed ID: 28830460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia.
    Papaioannou D; Nicolet D; Ozer HG; Mrózek K; Volinia S; Fadda P; Carroll AJ; Kohlschmidt J; Kolitz JE; Wang ES; Stone RM; Byrd JC; Garzon R; Bloomfield CD
    Mol Cancer Ther; 2019 Aug; 18(8):1451-1459. PubMed ID: 31164409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia.
    Zhang TJ; Wang YX; Yang DQ; Yao DM; Yang L; Zhou JD; Deng ZQ; Wen XM; Guo H; Ma JC; Lin J; Qian J
    Clin Lab; 2016; 62(1-2):113-20. PubMed ID: 27012040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MicroRNA expression in cytogenetically normal acute myeloid leukemia.
    Marcucci G; Radmacher MD; Maharry K; Mrózek K; Ruppert AS; Paschka P; Vukosavljevic T; Whitman SP; Baldus CD; Langer C; Liu CG; Carroll AJ; Powell BL; Garzon R; Croce CM; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD
    N Engl J Med; 2008 May; 358(18):1919-28. PubMed ID: 18450603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
    Whitman SP; Ruppert AS; Radmacher MD; Mrózek K; Paschka P; Langer C; Baldus CD; Wen J; Racke F; Powell BL; Kolitz JE; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    Blood; 2008 Feb; 111(3):1552-9. PubMed ID: 17940205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Ang Q; Wang GJ; Zhu J; Wang WD
    Oncotarget; 2016 Jan; 7(3):2585-95. PubMed ID: 26506237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
    Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
    Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.